RxDoctor Payments Data

Sari Capilouto

Gerontology · Montgomery, ALNPI 1316368475

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,800 of the $8,590 with a category attached, or 67.5%. Acadia Pharmaceuticals Inc accounts for 98.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $8,193 and has fallen 97.9% since, to $170 in 2024. Among gerontology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,590in general payments, 2019–2025

Across 38 payments — averaging $226.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$8K
  • Lilly USA, LLC$58
  • Neurocrine Biosciences, Inc.$55
  • UCB, Inc.$19
  • Philips North America LLC$15
  • Urovant Sciences Inc$15
  • plus $13 from 1 others

What the payments were for

  • Consulting fees$2002%
  • Speaking & faculty fees$5,80068%
  • Travel & lodging$1,38016%
  • Food & beverage$1,21114%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,590 in reported general payments places this provider in the 95th percentile of 143 gerontology providers in Alabama.

See all gerontology providers in Alabama

Medicare billing

Part B allowed, 2024
$85,470
Medicare patients
104
Services billed
1,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate24$64,901
Fluvoxamine Maleate23$1,032
Memantine Hcl16$652
Buspirone Hcl18$604
Quetiapine Fumarate24$554
AmantadineAmantadine Hcl12$404
Donepezil Hcl12$341
Aripiprazole12$312
Mirtazapine20$264
Lisinopril20$241
Famotidine18$199
Bumetanide11$156
Escitalopram Oxalate12$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$8,416$64,90124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 143 gerontology providers in Alabama.

Other gerontology in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →